Hormones and Cancer a Bright Future

Authors: Carol A Lange

Publish Date: 2012/01/19

Volume: 3, Issue: 1-2, Pages: 1-2

PDF Link

Abstract

Hormones impact all aspects of cancer biology from its earliest stages of development to its full progression towards malignancy Hormonal intervention is a keystone of cancer prevention and treatment and altered hormone sensitivity of cancer cells is a hallmark of cancer and a mechanism of chemoresistance As such the field of hormones and cancer is highly relevant to human health but we still have a lot to learn The founding editor of Hormones and Cancer Jonathan Li had the vision of formalizing this discipline as a combined focus by creating a publication home for highquality papers on translational research in hormoneassociated cancers Under his leadership the journal made important strides and met key milestones including acceptance into the Thomson Reuters ISI database April 2011 inclusion in the PubMed Database July 2011 and free online access for members of The Endocrine Society http//wwwendosocietyorg/journals/hormones cancercfm As the incoming editorinchief of Hormones and Cancer I am honored to continue Dr Li’s legacy and delighted to serve The Endocrine Society and Springer as an advocate for our fieldAs in the past Hormones and Cancer will remain committed to spanning basic translational and clinical research focus areas as a major priority We are perhaps unique from other cancer or endocrine journals in this regard and it is a clear strength of Hormones and Cancer Importantly the journal will retain its original strong presence in breast and gynecologic cancers in women and prostate cancer in men and will continue to include and solicit studies on hormonally influenced cancers of endocrine glands such as adrenal pituitary and thyroid organs Notably hormones are emerging as important regulators of a broad range of nontraditional as hormonedriven tumor types including cancers of the lung colon and hematopoietic tissues Additionally it is becoming clear that selected cancerlike benign illnesses are highly relevant to the field of hormones and cancer For example lymphangioleiomyomatosis or LAM is a progressive cystic lung disease that predominantly affects young women a high percentage ~30 of women with the tumor suppressor syndrome known as tuberous sclerosis complex develop pulmonary changes consistent with LAM and sporatic forms of the disease exist that are known to involve cancerassociated invasive and metastatic mechanisms Other syndromes of benign and malignant smooth muscle can mimic LAM benignmetastasizing leiomyoma endometrial stromal sarcomas and lowgrade leiomyosarcomas Inclusion of research articles from groups focused on understanding these cancerrelated illnesses will surely add depth to Hormones and Cancer by expanding our knowledge and complementing our existing readershipOther new additions to Hormones and Cancer include our updated cover design by The Endocrine Society’s Production Manager Cynthia Richardson We hope that readers will find the cover to be both artful and engaging and reflective of the quality of our content These are exciting times new discoveries continue to energize our basic and clinical research community Going forward it will be important to engage the full spectrum of hormones and cancerrelated research within the journal with the goal of defining a home forum for highimpact work that increases our understanding of how hormonally driven events shape cancer development progression and treatment This is critical for the science in the field and for defining the field for our scientists clinicians patients and funding agencies In sum I look forward to taking on my new duties as editorinchief and I invite you to advocate for our field by submitting your best work to Hormones and Cancer and by recommending the journal to your trainees and colleagues

Keywords: